A number of bills have been introduced in the 116th Congress to mitigate the impact of treatment and drug costs on U.S. patients. The ACR has reviewed the bills and supports those that most closely align with its positions on access to care.
Search results for: biosimilar
ACR Affiliate Society Council Spotlights State Efforts for Advocacy
So far it has been a busy year for the Affiliate Society Council (ASC). Forty-three states are now affiliated with the ACR through the ASC, and we may add another next year. Also, many state legislative sessions have wrapped up, so it’s a great time to provide an overview of the successes—and some of the…
Get Members Involved: That’s How Nevada Is Growing Its State Society
In April 2019, the Rheumatology Association of Nevada (RAN) hosted its fourth annual meeting. “We had the largest-ever number of attendees,” says RAN President Tim Kelly, MD, a rheumatologist in Las Vegas. Launched in 2016, RAN continues to grow, and Dr. Kelly hopes to see the statewide organization do more. “We want to expand our…
CMS Rule Reflects ACR’s Advocacy, but More Patient Protections Needed
In August 2018, the Centers for Medicare and Medicaid Services (CMS) announced it would permit Medicare Advantage plans to use step therapy for Part B drugs, with a lookback period of just 108 days.1Â On May 16, 2019, however, the CMS issued a final rule that extends the lookback period for Part B therapies to 365…
Rheumatology Drugs at a Glance, Part 2: Psoriasis
Over the past few years, bioÂsimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…
ACR Issues Position Statements on Key Rheumatology Issues
The ACR recently issued three new position statements on key issues facing rheumatologists and patients with rheumatic diseases: step therapy, affordable prescription drug pricing and a special waived test designation for synovial fluid crystal analysis performed by rheumatologists. Here is a detailed look at each. Addressing Step Therapy Step therapy or fail first protocols require patients…
Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…
U.S. FDA Chief Gottlieb Resigns
WASHINGTON (Reuters)—U.S. Food and Drug Administration (FDA) Chief Scott Gottlieb said he plans to step down in a month, calling into question how the agency will handle critical issues, such as e-cigarette use among teens and efforts to increase competition in prescription drugs. The U.S. Department of Health and Human Services (HHS), which oversees the…
Why & How Our Biologic Drug Discussion with Patients Should Evolve
As we turn the corner on the second decade of biologic use for rheumatic disorders, a reappraisal of approach in our communication with patients is due. In practice, the impact these agents have on patients’ lives justifies the friction rheumatologists face when connecting patients to them. You can understand why older rheumatologists who apprenticed on…
Canada Approves Erelzi for PsA; Plus FDA Moves to Increase Access to Naloxone
Health Canada has approved Erelzi, which is biosimilar to Enbrel (etanercept), for treating psoriatic arthritis in adults…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 42
- Next Page »